Abstract
Purpose
End-of-life cancer care varies widely, and very few centers evaluate it systematically. Our objective was to assess indicators of the aggressiveness of end-of-life cancer care in clinical practice.
Methods
An observational, longitudinal, and retrospective cohort study was conducted at a tertiary hospital. Eligible patients were at least 18 years old, had a solid tumor, were followed up by the Oncology Department, and had died because of cancer or associated complications during 2017. We used the criteria of Earle et al. (J Clin Oncol 21(6):1133–1138, 2003) to assess the aggressiveness of care. Multivariate logistic regression analyses were performed to characterize factors associated with aggressiveness of therapy.
Results
The study population comprised 684 patients. Eighty-eight patients (12.9%) received anti-cancer treatment during the last 14 days of their lives, and 62 patients (9.1%) started a new treatment line in the last 30 days. During the last month of life, 102 patients (14.9%) visited the ER, 80 patients (11.7%) were hospitalized more than once, and 26 (3.8%) were admitted to the ICU. A total of 326 patients (47.7%) died in the acute care unit. A total of 417 patients (61.0%) were followed by the Palliative Care Unit, and in 54 cases (13.0%), this care started during the last 3 days of life.
Conclusions
The use of anti-cancer therapies and health care services in our clinical practice, except for the ICU, did not meet the Earle criteria for high-quality care. Concerning hospice care, more than half of the patients received hospice services before death, although in some cases, this care started close to the time of death.
Similar content being viewed by others
References
Adelson K, Paris J, Horton JR, Hernandez-Tellez L, Ricks D, Morrison RS, Smith CB (2017) Standardized criteria for palliative care consultation on a solid tumor oncology service reduces downstream health care use. Journal of Oncology Practice 13(5):E431–EE40
Kim A, Fall P, Wang D (2005) Palliative care: optimizing quality of life. The Journal of the American Osteopathic Association 105(11 Suppl 5):S9–S14
Swarm RA, Dans M (2018) NCCN frameworks for resource stratification of NCCN guidelines: adult cancer pain and palliative care. J Natl Compr Cancer Netw 16(5):628–631
Wong ML, Lichtman SM, Morrow GR, Simmons J, Hargraves T, Gross CP et al (2019) Geriatric oncology health services research: cancer and aging research group infrastructure core. J Geriatr Oncol
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Palliative Care. Version 2.2019 [Available from: https://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf
Earle CC, Park ER, Lai B, Weeks JC, Ayanian JZ, Block S (2003) Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol 21(6):1133–1138
Earle CC, Neville BA, Landrum MB, Souza JM, Weeks JC, Block SD, Grunfeld E, Ayanian JZ (2005) Evaluating claims-based indicators of the intensity of end-of-life cancer care. Int J Qual Health Care 17(6):505–509
Cancer endorsement maintenance 2011. Final report. National Quality Forum. December 2012. [Available from: https://www.qualityforum.org/Projects/Cancer_Endorsement_Maintenance_2011.aspx
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology-Cancer Clinical Trials 5(6):649–655
European Medicines Agency. European public assessment reports [Available from: https://www.ema.europa.eu/en/medicines
Earle CC, Neville BA, Landrum MB, Ayanian JZ, Block SD, Weeks JC (2004) Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 22(2):315–321
Gilbar PJ, McPherson I, Aisthorpe GG, Kondalsamy-Chennakes S (2019) Systemic anticancer therapy in the last 30 days of life: retrospective audit from an Australian regional Cancer Centre. J Oncol Pharm Pract 25(3):599–606
Schulkes KJG, van Walree IC, van Elden LJR, van den Bos F, van Huis-Tanja L, Lammers JWJ, et al. Chemotherapy and healthcare utilisation near the end of life in patients with cancer. European Journal of Cancer Care. 2018;27(2)
Santos Pérez MI, Godoy Díez M, Abajo del Álamo C. Chemotherapy at the end of life: uncommon clinical practice? Journal of Healthcare Quality Research 2019;34(4):201–207
Duarte FJB, Calvo MSR, Pan JRA (2017) Therapeutic aggressiveness and liquid oncology. Cuadernos De Bioetica 28(92):71–81
Baena-Canada JM, Campini Bermejo A, Gamez Casado S, Rodriguez Perez L, Quilez Cutillas A, Calvete Candenas J et al (2019) Experiences with prescribing large quantities of systemic anticancer therapy near death. J Palliat Med
Colombet I, Bouleuc C, Piolot A, Vilfaillot A, Jaulmes H, Voisin-Saltiel S et al (2019) Multicentre analysis of intensity of care at the end-of-life in patients with advanced cancer, combining health administrative data with hospital records: variations in practice call for routine quality evaluation. Bmc Palliative Care 18:35
Taberner Bonastre P, Taberner Bonastre MT, Soler Company E, Perez-Serrano Lainosa MD (2016) Chemotherapy near the end of life; assessment of the clinical practise in onco-hematological in adult patients. Farm Hosp 40(1):14–24
Bahler C, Signorell A, Blozik E, Reich O (2018) Intensity of treatment in Swiss cancer patients at the end-of-life. Cancer Manag Res 10:481–491
Fang P, Jagsi R, He W, Lei X, Campbell EG, Giordano SH, Smith GL (2019) Rising and falling trends in the use of chemotherapy and targeted therapy near the end of life in older patients with cancer. J Clin Oncol 37(20):1721–1731
Zhang Z, Chen ML, Gu XL, Liu MH, Zhao WW, Cheng WW (2018) Palliative chemotherapy near the end of life in oncology patients. Am J Hosp Palliat Med 35(9):1215–1220
De Roo ML, Leemans K, Claessen SJJ, Cohen J, Pasman HRW, Deliens L et al (2013) Quality indicators for palliative care: update of a systematic review. J Pain Symptom Manag 46(4):556–572
Natsume M, Watanabe K, Matsumoto S, Naruge D, Hayashi K, Furuse J, Kawamura M, Jinno H, Sano K, Fukushima R, Osawa G, Aruga E, Hashiguchi Y, Tanaka A, Takikawa H, Seki N (2018) Factors influencing cancer patients’ choice of end-of-life care place. J Palliat Med 21(6):751–765
Norton SA, Wittink MN, Duberstein PR, Prigerson HG, Stanek S, Epstein RM (2019) Family caregiver descriptions of stopping chemotherapy and end-of-life transitions. Support Care Cancer 27(2):669–675
Bekelman JE, Halpern SD, Blankart CR, Bynum JP, Cohen J, Fowler R, Kaasa S, Kwietniewski L, Melberg HO, Onwuteaka-Philipsen B, Oosterveld-Vlug M, Pring A, Schreyögg J, Ulrich CM, Verne J, Wunsch H, Emanuel EJ, for the International Consortium for End-of-Life Research (ICELR) (2016) Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries. Jama-Journal of the American Medical Association 315(3):272–283
Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2017;35(1):96−+
Kaasa S, Loge JH, Aapro M, Albreht T, Anderson R, Bruera E, Brunelli C, Caraceni A, Cervantes A, Currow DC, Deliens L, Fallon M, Gómez-Batiste X, Grotmol KS, Hannon B, Haugen DF, Higginson IJ, Hjermstad MJ, Hui D, Jordan K, Kurita GP, Larkin PJ, Miccinesi G, Nauck F, Pribakovic R, Rodin G, Sjøgren P, Stone P, Zimmermann C, Lundeby T (2018) Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncol 19(11):E588–E653
Haun MW, Estel S, Rucker G, Friederich HC, Villalobos M, Thomas M et al (2017) Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev 6
Andreis F, Rizzi A, Rota L, Meriggi F, Mazzocchi M, Zaniboni A (2011) Chemotherapy use at the end of life. A retrospective single Centre experience analysis. Tumori. 97(1):30–34
Ziegler LE, Craigs CL, West RM, Carder P, Hurlow A, Millares-Martin P, et al. Is palliative care support associated with better quality end-of-life care indicators for patients with advanced cancer? A retrospective cohort study. BMJ Open. 2018;8(1)
Wang SY, Hsu SH, Huang S, Doan KC, Gross CP, Ma XM (2018) Regional practice patterns and racial/ethnic differences in intensity of end-of-life care. Health Serv Res 53(6):4291–4309
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
The study was performed according to the ethics committee of the participating hospital and the Helsinki Declaration.
Conflict of interest
The authors declare that they have no conflict of interest
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOC 290 kb)
Rights and permissions
About this article
Cite this article
García-Martín, E., Escudero-Vilaplana, V., Fox, B. et al. Aggressiveness of end-of-life cancer care: what happens in clinical practice?. Support Care Cancer 29, 3121–3127 (2021). https://doi.org/10.1007/s00520-020-05828-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-020-05828-9